Answers are grounded in this paper and cite their sources.
Preclinical treatment with NLGM1 improves outcomes in ischemic stroke, suggesting a new neuroprotective strategy.
Treatment of mice with NLGM1 resulted in reduced brain infarct size acutely following intraluminal MCAO and improved motor and behavior function acutely and chronically following intraluminal and PT MCAO. NLGM1 represents a promising novel neuroprotective agent in stroke.
No takes yet. Share an insight, caveat, or question.
Ahmad et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: